Skip to main content
Industry News
Agios: Mitapivat shows positive effect on hemoglobin of SCD patients

Agios Pharmaceuticals, developer of AG-348, or mitapivat, reported that preliminary phase I trial data showed the drug safely boosted hemoglobin amounts and altered biomarker levels of red blood damage in adult patients with sickle cell disease. The NIH-backed trial is already underway and aims to enroll 25 participants, with patient recruitment currently ongoing.

Full Story: